Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group

Rucker, FG; Agrawal, M; Corbacioglu, A; Weber, D; Kapp-Schwoerer, S; Gaidzik, VI; Jahn, N; Schroeder, T; Wattad, M; Lubbert, M; Koller, E; Kindler, T; Gotze, K; Ringhoffer, M; Westermann, J; Fiedler, W; Horst, HA; Greil, R; Schroers, R; Mayer, K; Heinicke, T; Krauter, J; Schlenk, RF; Thol, F; Heuser, M; Ganser, A; Bullinger, L; Paschka, P; Dohner, H; Dohner, K

View this publication in the PUBMED database